This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Adaptive Biotechnologies's Median PS Value or its related term are showing as below:
ADPT's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.87 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Adaptive Biotechnologies (NAS:ADPT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Adaptive Biotechnologies's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
19.34
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies Median PS Value Related Terms
Adaptive Biotechnologies Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADPT vs GRAL, WGS, NEO: Median PS Value Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Adaptive Biotechnologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.887.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (ADPT) has a Median PS Value of $0.00 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #999999 out of 86 companies in the Medical Diagnostics & Research industry.
Is Adaptive Biotechnologies' Median PS Value too high?
Adaptive Biotechnologies' current Median PS Value is $0.00. Based on the distribution chart, Adaptive Biotechnologies ranks #999999 out of 86 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Median PS Value compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #999999 out of 86 companies for Median PS Value. This places Adaptive Biotechnologies in the lower half of its industry. The industry median Median PS Value is 0.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.87, based on 86 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $19.34 — trading 92.2% above its estimated fair value. The current Median PS Value is $0.00. Adaptive Biotechnologies' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Median PS Value is $0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of $19.34 is trading 92.2% above its estimated GF Value™ of $10.06.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for ADPT:
Median PS Value: $0.00
GF Value™: $10.06 vs. price of $19.34 (92.2% above fair value)
No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
73GF Score
Get the complete analysis for ADPT
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADPT has been successfully added to your 
